ARB 011
Alternative Names: ARB-011Latest Information Update: 15 Jun 2024
At a glance
- Originator Arbele
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; RNA
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 15 Jun 2024 Pharmacodynamics data from the preclinical studies trial in Gastrointestinal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 06 Jul 2023 Arbele has patent pending for ARB 011 in Europe, China and South Korea
- 06 Jul 2023 Arbele has patent protection for ARB 011 in Australia, Israel, China, Japan, USA